Veracyte Inc’s filing revealed that its Officer JOHN LEITE acquired Company’s shares for reported $0.24 million on Mar 07 ’25. In the deal valued at $32.51 per share,7,411 shares were bought.
Then, ANN MCGUIRE bought 1,142 shares, generating $38,326 in total proceeds.
Before that, MARC STAPLEY bought 52,697 shares. Veracyte Inc shares valued at $1,768,511 were divested by the Director at a price of $33.56 per share.
Goldman downgraded its Veracyte Inc [VCYT] rating to a Neutral from a a Buy in a research note published on December 05, 2024; the price target was decreased to $37 from $38. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who began to cover the stock in mid November with a ‘”an Outperform”‘ rating. UBS began covering VCYT with “Buy” recommendation on October 16, 2024. Guggenheim started covering the stock on October 10, 2024. It rated VCYT as “a Buy”.
Price Performance Review of VCYT
On Friday, Veracyte Inc [NASDAQ:VCYT] saw its stock fall -1.51% to $32.02. Over the last five days, the stock has lost -7.88%. Veracyte Inc shares have fallen nearly -19.14% since the year began. Nevertheless, the stocks have risen 39.52% over the past one year. While a 52-week high of $47.32 was reached on 01/30/25, a 52-week low of $18.61 was recorded on 03/07/25. SMA at 50 days reached $40.58, while 200 days put it at $33.07.
Levels Of Support And Resistance For VCYT Stock
The 24-hour chart illustrates a support level at 30.52, which if violated will result in even more drops to 29.01. On the upside, there is a resistance level at 33.10. A further resistance level may holdings at 34.17. The Relative Strength Index (RSI) on the 14-day chart is 32.01, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -3.57, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 84.24%. Stochastics %K at 10.36% indicates the stock is a buying.
The most recent change occurred on February 23, 2024 when Needham resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $33.
